Tumor necrosis factor inhibitor-associated dermatomyositis - Wikidata - awgldk - TriplyDB

Tumor necrosis factor inhibitor-associated dermatomyositis

Tumor necrosis factor inhibitor-associated dermatomyositis

http://www.wikidata.org/entity/Q34015824

about

Treatment of inflammatory myopathy: emerging therapies and therapeutic targets Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies Immunotherapies for Immune-Mediated Myopathies: A Current Perspective Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.Novel regulation of CCL2 gene expression by murine LITAF and STAT6B.Cutaneous dermatomyositis: an updated review of treatment options and internal associations.A randomized, pilot trial of etanercept in dermatomyositis.Diagnosis and treatment of the idiopathic inflammatory myopathies Vasculitis associated with tumor necrosis factor-α inhibitors Novel transcriptional regulation of VEGF in inflammatory processes Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel.Paradoxes in dermatology.Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought.Amicrobial pustulosis-like rash in a patient with Crohn's disease under anti-TNF-alpha blocker.Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors.Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?Management of cutaneous dermatomyositis.Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.Frequency and spectrum of myopathies in patients with psoriasis.Three cases of anti-TNF induced myositis and literature review.Update on the pharmacological treatment of adult myositis.Cutaneous side-effects of biologics in immune-mediated disorders: A histopathological perspective.Pharmacological management of dermatomyositis.Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review.Etanercept-induced myositis: do we have to stop it? A surprising outcome.The Vasculopathy of Juvenile Dermatomyositis New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review

P2860

Q26796546-14A98F4A-F663-440D-BB34-C16CEF49F5D0 Q26863125-3F2F5435-C644-4E7F-9E0B-08533CF66433 Q30699742-1689027F-AA54-45BC-86A7-D2395FCA4862 Q33717793-459C1E30-0BFD-4AAF-9B6E-983DDA996CE8 Q34042924-2CDF32A6-912C-4B5A-84AA-89AC1188CDD6 Q34349952-1B9F169E-1609-436C-AA77-53A6972FAC80 Q35206687-1290D10E-D565-48C0-B36F-A33906F1114E Q36059440-1EBADF9C-CC66-4969-A0A8-8FDC9A3113BB Q36513081-CF085F6B-6D9F-4498-8D5A-19ACAE8529DF Q36728178-0D29A42D-E3F5-4E1C-B514-F18986E90B4E Q36766536-D067D0D1-E66B-4A4E-9397-4D1237FFBCD4 Q36904729-0A9A79BB-3F92-43E6-BC4B-B5392682113E Q37095730-10EA891F-B88E-4674-A7DC-FD61E15CB2F5 Q37830968-75208FEB-85AF-40C6-AA51-9382185B0167 Q37901281-337C1F66-B42E-4D40-BE30-BFB7C451A06F Q37911726-D00840DF-6CC5-4D03-9C56-0EE511E7E016 Q38003700-4F485DDE-9B20-4C6E-8075-478A949841B2 Q38022271-1E04EEA0-B013-4AB1-B95E-7E5F1E4E6532 Q38099248-1E829D92-309D-4613-B480-F0FB6F7A55DB Q38137819-5B563AB3-A222-406C-BD03-13C6C52E5FA8 Q38785400-993A618E-CFC6-41E8-A8F7-CA4C054BF434 Q38813275-6F5405E5-DDF8-4837-AC05-5C8CAD0BA565 Q39159787-D8DEB033-DA6B-4CC8-9DD0-A3CC37C3CB70 Q39425296-33F843BB-45B3-44D3-A250-10B2C9FDA300 Q47235167-0CA64793-3BB7-470B-AEB1-707487D55AE9 Q54541002-7160F490-8BFE-4041-95BB-7E95C3EA1138 Q57816912-99984C7A-8D85-41F7-B9A0-2758A9B5C34F Q59074825-640C4B05-2D47-408F-B885-DF5013DEB718

P2860

Tumor necrosis factor inhibitor-associated dermatomyositis

http://www.wikidata.org/entity/Q34015824

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Tumor necrosis factor inhibitor-associated dermatomyositis

@ast

Tumor necrosis factor inhibitor-associated dermatomyositis

@en

Tumor necrosis factor inhibitor-associated dermatomyositis

@nl

type

label

Tumor necrosis factor inhibitor-associated dermatomyositis

@ast

Tumor necrosis factor inhibitor-associated dermatomyositis

@en

Tumor necrosis factor inhibitor-associated dermatomyositis

@nl

prefLabel

Tumor necrosis factor inhibitor-associated dermatomyositis

@ast

Tumor necrosis factor inhibitor-associated dermatomyositis

@en

Tumor necrosis factor inhibitor-associated dermatomyositis

@nl

P1433

Q34015824-D0F7313A-7943-49BD-A2E6-4C8F627444E2

P1476

Q34015824-27ABA9A5-CB44-48B1-8D09-3B7181FF47F9

P2093

Q34015824-6A6BB522-32A6-40B4-B6CA-B2870800EAD2

Q34015824-70BBC9B2-F132-4BB4-ADE3-2285057925EF

Q34015824-7F2F5141-D6F1-46FA-9618-F414ECA340C1

Q34015824-8303F0F1-952A-46F0-BA58-9990E4AC17DE

Q34015824-A7BE4753-36E6-4F2E-9518-C92B4DE498FC

Q34015824-D9C6A531-6624-415A-A2DC-61EC8948AA1C

P2860

Q34015824-004A375D-C978-4510-95A8-7A824AC937DD

Q34015824-18610645-D71E-426E-ACC4-4597E509CD1C

Q34015824-1EE31399-1EAB-4C72-A6BD-685D69F24637

Q34015824-2B07A9EB-087F-432B-B9C4-5D1C95743C7F

Q34015824-2C0B0227-DC0E-4453-8A95-86BFDBA010ED

Q34015824-2D1C4615-2528-4AB2-B74E-E276B581B6CD

Q34015824-3BB3406C-C97C-4AEB-94A9-C78957914018

Q34015824-4AF47A31-597C-44F4-A2A5-F7CF51C6FD30

Q34015824-54D82699-CCEF-44B5-991E-73C355F0B6B5

Q34015824-57C438D7-5F71-413C-B5ED-5DD59EC6A222

P304

Q34015824-5A333DCA-DD08-4895-9134-3D8A785D0215

P31

Q34015824-CACDD84D-3F8E-4045-856C-6A8625B9355C

P356

Q34015824-8D51A15E-5FA4-47CF-BCFB-A8549F22B466

P433

Q34015824-384C4B83-0309-4789-A24A-289DDA46DB22

P478

Q34015824-02839CD0-8D3F-4E9B-8588-CA0EDE0F88E8

P577

Q34015824-112BEF1C-A38D-43AB-9039-17BFE2C7BF04

P5875

Q34015824-9F334F1B-C72B-42D5-A905-EF67591EE4EA

P698

Q34015824-C67AEEB3-52EC-4E39-9AFA-FD48ACAAD970

P921

Q34015824-AC7508EF-0E73-44E1-B27C-6874FAC7329B

P932

Q34015824-A16DBA36-9F9A-46F9-B76D-B5EA8EF76BDD

P356

ARCHDERMATOL.2010.142

P1433

JAMA Dermatology

P1476

Tumor necrosis factor inhibitor-associated dermatomyositis

@en

P2093

Brian Kim

http://www.w3.org/2001/XMLSchema#string

Ellen J Kim

http://www.w3.org/2001/XMLSchema#string

Jonathan Dunham

http://www.w3.org/2001/XMLSchema#string

Misha Rosenbach

http://www.w3.org/2001/XMLSchema#string

Rachel Klein

http://www.w3.org/2001/XMLSchema#string

Victoria P Werth

http://www.w3.org/2001/XMLSchema#string

P2860

Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.

Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy.

Role of apoptosis in autoimmunity.

Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics.

Possible pathogenic mechanisms in inflammatory myopathies.

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.

P304

780-784

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHDERMATOL.2010.142

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45275203

http://www.w3.org/2001/XMLSchema#string

P698

20644041

http://www.w3.org/2001/XMLSchema#string

P921

dermatomyositis

P932

2909024

http://www.w3.org/2001/XMLSchema#string